Investment Rating - Buy | Maintain [2] Core Views - The company's full-year performance exceeded expectations, with significant optimization in H2 sales expense ratio [3] - The product matrix continues to enrich, with strong growth in key brands and new product launches [4] - The company maintains a leading position in the recombinant collagen protein market, supported by strong R&D capabilities and industry standards [3][4] Financial Performance - 2023 revenue reached 3,524 million RMB, a year-on-year increase of 49.05% [3] - Net profit attributable to the parent company was 1,452 million RMB, up 44.88% year-on-year [3] - Gross margin was 83.63%, a slight decrease of 0.76 percentage points, while net margin was 41.19%, down 0.98 percentage points [3] - Sales expense ratio was 33.04%, up 3.17 percentage points, but showed significant optimization compared to H1 [3] - Management expense ratio decreased by 1.95 percentage points to 2.74%, while R&D expense ratio increased by 0.26 percentage points to 2.13% [3] Product and Brand Performance - Key brand "Kefumei" achieved revenue of 2,788 million RMB, a year-on-year increase of 72.86% [4] - "Kefumei" collagen repair series saw strong growth, with GMV during Double 11 increasing by over 200% [4] - New products such as "Collagen Milk" and "Collagen Soothing Patch" frequently appeared on Tmall and Douyin bestseller lists [4] - "Keling" brand revenue remained stable at 617 million RMB, with star products continuing to perform well [4] Channel and Operational Strategy - Direct sales channels accounted for 68.7% of total revenue, with online direct sales contributing 61.2%, up 77.5% year-on-year [4] - Distribution channels accounted for 31.3% of revenue, up 14.6% year-on-year [4] - The company expanded its offline presence, opening its first "Kefumei" standard store in Xi'an and three "Keling" specialty stores [4] - Production capacity increased with the completion of new recombinant collagen protein fermentation workshops and additional production lines [4] Future Outlook and Profit Forecast - The company is expected to achieve net profit attributable to the parent company of 1,721 million RMB in 2024, 2,196 million RMB in 2025, and 2,743 million RMB in 2026 [5] - Corresponding P/E ratios are projected at 23x, 18x, and 14x for 2024-2026 [5] - The company is positioned as a leader in the professional skincare market, with a strong focus on R&D and brand expansion [5]

Investment Rating - The report gives an "Accumulate" rating for the company, indicating a positive outlook for future performance [35][156]. Core Insights - The company has a strong historical foundation in the pharmaceutical industry and is actively expanding into the health and wellness sector, leveraging its financial strengths to drive growth [42][50]. - The traditional Chinese medicine segment is expected to maintain a high growth rate, with projected revenue growth rates of 20.7%, 15.5%, and 13.7% for 2023-2025 [154]. - The chemical drug segment is anticipated to recover gradually, with significant growth expected from products like L-lysine and other small varieties [20][107]. - The health and wellness business is experiencing rapid growth, with a revenue increase of 303.76% in the first half of 2023 compared to the previous year [137]. Summary by Sections 1. Company Overview - The company, Jilin Aodong Pharmaceutical Group, has a long history dating back to 1957 and has evolved into a large-scale enterprise focusing on pharmaceuticals and health products [42][50]. - The company has a stable shareholding structure, with key management continuously increasing their stakes, which enhances investor confidence [46][57]. 2. Traditional Chinese Medicine (TCM) - TCM products have shown steady growth, with significant contributions from core products such as Anshen Bnnao Liquid, Xiaoer Chaigui Oral Liquid, and Xuefu Zhuyu Oral Liquid [50][89]. - The company is expanding its production capacity for TCM formula granules, which are expected to capture a larger market share [78][154]. 3. Chemical Drugs - The chemical drug segment has faced challenges due to regulatory impacts but is expected to stabilize and recover, particularly with the removal of certain products from monitoring lists [20][107]. - Sales of L-lysine and other chemical drugs are projected to grow significantly, contributing to the overall revenue recovery [20][107]. 4. Health and Wellness Sector - The health and wellness segment is rapidly expanding, with a focus on dietary supplements and functional foods, which are projected to see substantial revenue growth [137][148]. - The company is leveraging e-commerce and digital marketing strategies to enhance sales in this sector [139]. 5. Financial Performance and Projections - The company forecasts net profits of 2.76 billion, 3.26 billion, and 3.79 billion yuan for 2023-2025, reflecting significant growth rates [22][156]. - The projected total market value of the company is estimated at 223.7 billion yuan, indicating that the current market valuation is undervalued [156].

Investment Rating - The report initiates coverage with a "Buy" rating for Dongfang Cable (603606.SH) [2][3]. Core Views - The company reported a revenue of 7.31 billion yuan in 2023, a year-on-year increase of 4.3%, and a net profit attributable to shareholders of 1 billion yuan, up 18.8% year-on-year [2][7]. - The company's cash flow from operating activities significantly improved, reaching 1.19 billion yuan in 2023, an increase of 83.9% year-on-year [2][14]. - The company is expected to benefit from the recovery of the offshore wind industry, with a projected high growth in orders for 2024 [2][14]. - The company is actively expanding its overseas market presence through investments in foreign companies [2][15]. Financial Performance - In 2023, the revenue breakdown was as follows: land cables 3.83 billion yuan (down 3.8%), submarine cables 2.77 billion yuan (up 23.5%), and marine engineering 710 million yuan (down 9.9%) [2][10]. - The gross margin for submarine cables reached 49.14% in 2023, an increase of 5.9 percentage points year-on-year, contributing to an overall gross margin of 25.2%, up 2.8 percentage points [2][10]. - The company’s net profit is projected to grow to 1.3 billion yuan in 2024, reflecting a year-on-year increase of 30% [2][3]. Order Backlog and Market Outlook - As of March 15, 2024, the company had an order backlog of 7.86 billion yuan, with land cables at 3.75 billion yuan (up 73.1%), submarine cables at 3.16 billion yuan (down 45%), and marine engineering at 950 million yuan (down 21.7%) [2][14]. - The report anticipates a recovery in the offshore wind sector, which is expected to drive significant order growth for the company in 2024 [2][14]. Overseas Expansion - In January 2024, the company announced plans to invest in Xlinks First and XLCC, acquiring 2.4% and 8.5% stakes respectively, to enhance its overseas market presence [2][15].

[Table_Main] 公司研究|信息技术|技术硬件与设备 证券研究报告 柏楚电子(688188)公司点评报告 2024年03月23日 [Table_Invest] [Tab业le_T绩itle实] 现快速增长，积极开拓海外市场 买入|维持 ——柏楚电子(688188.SH)2023年年度报告点评 [当Ta前b价le_：T argetPr2ic7e4]. 77元 [事Ta件ble：_S ummary] 公司于2024年3月19日收盘后发布《2023年年度报告》。 [基Ta本bl数e_据Ba se] 点评： 52周最高/最低价（元）： 296.01 / 178.56  收入与利润实现快速增长，市场开拓成效显著 A股流通股（百万股）： 146.33 2023年，虽然国内外下游环境仍在一定程度上受到宏观经济的部分影响， A股总股本（百万股）： 146.33 但是受益于国内高功率厚板切割需求的持续增长及国外应用场景的持续拓 流通市值（百万元）： 40208.21 展，公司主营业务依然实现较快增长。公司全年实现营业收入14.07亿元， 总市值（百万元）： 40208.21 同比增长56.61%；实现归母净利润7.2 ...

[Table_Main] 公司研究|日常消费|食品与主要用品零售Ⅱ 证券研究报告 [Table_Title] 高端性价比，改革见成效 | --- | --- | --- | --- | --- | --- | |-----------------------|---------|---------|---------|----------|----------| | 财务数据和估值 | 2022A | 2023A | 2024E | 2025E | 2026E | | 营业收入 ( 百万元 ) | 7293.16 | 7114.58 | 9594.10 | 11726.15 | 14072.80 | | 收入同比 (%) | -25.35 | -2.45 | 34.85 | 22.22 | 20.01 | | 归母净利润 ( 百万元 ) | 129.40 | 219.79 | 299.54 | 381.37 | 475.06 | | 归母净利润同比 (%) | -68.52 | 69.85 | 36.28 | 27.32 | 24.56 | | ROE(%) | 5.52 | 8.74 | 10.88 | 1 ...

Investment Rating - The report maintains a "Buy" rating for the company [3][8]. Core Insights - The company experienced short-term pressure on its performance, with total revenue of 5.242 billion yuan, a year-on-year decrease of 3.73%. The net profit attributable to shareholders was 466 million yuan, down 39.36% year-on-year [5]. - The smart automotive business achieved rapid growth, generating revenue of 2.337 billion yuan, an increase of 30.34% year-on-year. The smart driving software revenue reached 182 million yuan, marking a historic breakthrough [5]. - The Internet of Things (IoT) business generated revenue of 1.489 billion yuan, a decline of 15.45% year-on-year, but showed signs of recovery in the second half of 2023 [5]. - The smart software business reported revenue of 1.416 billion yuan, down 25.12% year-on-year, but is expected to benefit from the integration of artificial intelligence and smartphones [5]. Business Development - The company is focusing its core resources on key clients to maintain competitive advantages for long-term development [5]. - A strategic upgrade in edge intelligence has been initiated, showcasing the company's capabilities in various applications, including smart automotive solutions and AI-enabled PC products [6]. - The establishment of a robotics team in September 2023 marks a significant step in the company's strategic transformation, with products aimed at warehouse logistics and manufacturing automation [7]. Financial Forecast and Investment Suggestions - The company is projected to achieve revenues of 6.042 billion yuan, 6.827 billion yuan, and 7.592 billion yuan for 2024, 2025, and 2026, respectively. The net profit attributable to shareholders is expected to be 662 million yuan, 796 million yuan, and 922 million yuan for the same years [8]. - The earnings per share (EPS) is forecasted to be 1.44 yuan, 1.73 yuan, and 2.00 yuan for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios of 44.45, 36.98, and 31.93 [8].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4][77]. Core Insights - The coronary artery disease (CAD) diagnosis market in China has significant growth potential, with over 11 million patients and a long-term market space expected to exceed 4 billion [1]. - The innovative drug, Dexmedetomidine Hydrochloride, is anticipated to be a new growth driver, with a market space exceeding 1 billion [1]. - The integration of raw material and formulation development is expected to sustain steady growth in traditional business [1]. - The company is projected to achieve revenues of 1.305 billion, 1.442 billion, and 1.576 billion from 2023 to 2025, with corresponding net profits of 71 million, 120 million, and 160 million [39]. Summary by Sections 1. Integrated Development of Raw Materials and Formulations - The company has established a diversified business structure in raw materials, including antihypertensive and proton pump inhibitors, with a production base in Jingmen, Hubei [1][38]. - The company’s formulation business is expected to benefit from centralized procurement, leading to rapid sales growth [62]. 2. Innovative Drug Dexmedetomidine Hydrochloride - The drug is in the final stages of clinical trials and is expected to be launched soon, with a market potential of over 1 billion [1][27]. - The penetration rate of nuclear myocardial perfusion imaging (MPI) in China is currently low, indicating substantial room for growth [1]. 3. Financial Forecast and Investment Recommendations - The company is expected to achieve revenues of 1.305 billion, 1.442 billion, and 1.576 billion from 2023 to 2025, with net profits of 71 million, 120 million, and 160 million respectively [39]. - The earnings per share (EPS) are projected to be 0.21, 0.36, and 0.48 for the same period, with corresponding price-to-earnings (PE) ratios of 53, 31, and 23 [39].

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation of stock price appreciation exceeding 20% over the next six months [5]. Core Insights - The company has shown a significant recovery in profitability, with a 49.43% year-on-year increase in revenue to 5.986 billion yuan and an 820.17% increase in net profit to 453 million yuan, achieving a net profit margin of 8.02% [2][5]. - The company is expanding its store network steadily, opening 180 new restaurants in 2023, bringing the total to 726 locations by year-end [3]. - The company is enhancing shareholder returns through increased dividends, proposing a final dividend of 0.15 HKD per share, which represents a payout ratio of approximately 43.1% of the annual profit attributable to equity shareholders [4]. Summary by Sections Financial Performance - In 2023, the company achieved a total revenue of 5.986 billion yuan, a 49.43% increase from the previous year. The net profit reached 453 million yuan, marking an 820.17% increase, with a net profit margin improvement of 6.63 percentage points compared to 2022 [2][9]. - The cost structure improved, with raw material costs, employee costs, and depreciation and rental costs as a percentage of revenue decreasing by 0.34, 2.51, and 1.71 percentage points, respectively [2]. Brand Development and Expansion - The company follows a multi-brand strategy, with significant contributions from its main brands: Tai Er, Jiu Mao Jiu, and Song Hot Pot, which generated revenues of 4.477 billion, 630 million, and 808 million yuan, respectively, in 2023 [3]. - The company has successfully launched new brands, including Shuang Xian Yue Mu and Shan Wai Mian, with the latter already generating revenue of 7.17 million yuan from its single restaurant [3]. Shareholder Returns - The company has allocated 150 million HKD for share buybacks and has proposed a final dividend, aiming to maintain a payout ratio of no less than 40% of the annual profit attributable to equity shareholders in the future [4].

[Table_TargetPrice] [Table_Title] 23 年业绩增长亮眼，薇旖美快速放量 [Table_Summary] 事件： 公司发布 2023 年年报。 23 年业绩增长亮眼，盈利能力明显优化 单一材料医疗器械及功能护肤品实现高增，原料业务积极开拓 薇旖美快速放量，战略合作欧莱雅强化行业领先地位 研发高投入加码功能蛋白创新，在研管线储备丰富 投资建议与盈利预测 | --- | --- | --- | |-------|------------------------------|--------------------| | | | | | | [Table_Base 基本数据 ] | | | | 52 周最高 / 最低价（元）： | 302.33/112.60 | | | A 股流通股（百万股）： | 23.66 | | | A 股总股本（百万股）： | 68.09 | | | 流通市值（百万元）： | 15,026.58 | | | 总市值（百万元）： | 15,026.58 | | | [Table_ 报告作者 Author] | | | | 分析师 | | | | 执业证书编号 ...

2024 年 03 月 24 日 投资要点： 宏观经济：虽然金融周期至此，但当前靠全球定价的库存周期，经济增长 也能暂时性稳住，经济基本面不是定价资产的核心线索。 资产配置：流动性梗阻现象映射在资产配置上就是持续性的 risk-off，这 超出了周期定义的范畴。 利率债：关注后续政策的落地。但目前来看，债券市场不必恐高，在趋势 出现扭转迹象之前，利率债应会一直处于占优状态。 信用市场：在风控允许的范围内，可以尽可能下潜城投信用，目前看，在 极端的配置图景下，信用利差有历史性新低的可能；但是地产信用还要等等。 商品市场：从绝对价格的角度，当前商品价格是偏高的，但从周期意义上 说，商品可能即将出现一个上行的波段，但可以略微注意的是，竣工的速度在 大幅下滑，玻璃价格上涨的逻辑已经不复存在。 [Table_PicStock 主要市场走势图] [Table_Report] 相关研究报告 《宏观与大类资产周报：有为方治》2024.03.17 | --- | --- | |------------------------|------------------------| | [Table_Author 报告作者 | ] ...